Program 03 Planned

Scattered records,
turned into usable data

The Data Lab is in preparation. It is planned to refine separately consented before and after records for research and clinical studies, once research partners and data processing arrangements are in place.

Planned recordsConsented before and after recordsSurveys · photos · check-ins
What we makeDe-identified aggregate dataCleaning · standardizing · quality checks
Where it goesResearch · clinical studies · data provisionStarts once partners are secured
Background

Placenta and cord derived stem cells, what are they?

The umbilical cord and the placenta are distinct tissues. Professor Phan Toan Thang’s team studied the outer lining of the cord. The cross-section below shows where that lining sits.

ABC
A · Cord liningThe outer membrane around the cord. Cells from here are cord lining derived stem cells.
B · Inner tissueA jelly like tissue around the vessels that cushions and protects them.
C · Cord bloodThe blood that flowed through the cord vessels. Cells from here are cord blood derived stem cells.
Birth→Mother consents to donation→Tissue separation→Testing · storage→Research · use

No embryos are used. Because these cells are only available after a birth, supply is tied to the number of births, and collection and storage standards are strict.

Research background

This is how far public research has come

Only publicly verifiable facts in this field are listed. They are not evidence of efficacy or approval for any Cellumium program.

2004

Cord lining stem cell patent filed

Priority date of CellResearch Corp's root patent on isolating stem cells from the umbilical cord lining (16 Aug 2004).

See the records in Science
Patent

US patent granted

A US patent on isolating and using cord lining stem cells.

Patent number to be added
Phase 1

Diabetic foot ulcer trial

A cell therapy candidate from the same company is in a US FDA phase 1 trial. Phase 1 is an early stage that checks safety.

Trial registration number to be added
Next

Real world records

Before and after records of people who used a program. This has never been gathered systematically. It is the gap the Data Lab aims to fill.

How the data flows

From consent to provision

Each step opens only after the one before it is in place. Current status is shown for each.

01

Consent

Consent is collected separately for each purpose. You can withdraw it and request deletion at any time.

In preparation
02

Records

Future studies would collect their own before and after surveys, photos and check-ins with research-specific consent. The current health survey is for personal use.

In preparation
03

Refining

Names and contact details are removed, formats are aligned, and missing or inconsistent values are filtered out.

Planned
04

Research · clinical

Observational studies are designed with research partners, and as evidence builds they lead to clinical trials.

Planned
05

Data provision

We plan to provide de-identified aggregate data to research institutions and companies, subject to purpose-specific consent and agreements.

Planned
Steps to clinical trials

From records to approval

Claims of efficacy need clinical evidence, and clinical trials need records to be designed. The Data Lab is being designed to support the first two steps.

Where the Data Lab fits
01

Records

Before and after, recorded with the same questions.

02

Observational study

Records are studied without intervention to form hypotheses. Requires ethics review.

Public example in this field: phase 1
03

Phase 1

A small group. Checks safety.

04

Phase 2

Explores dose and effect.

05

Phase 3

Confirms effect and safety at scale.

06

Approval

Review and approval by regulators.

Cellumium and the Data Lab do not provide medical services. Clinical trials are approved and run by medical institutions and regulators. Step 03 and beyond start only once a research partner is in place.

Data provision Planned

Who can use the refined data?

These are potential recipients, not signed contracts. Provision starts only after refining and consent are in place.

Who

Potential recipients

  • Universities and institutes researching regenerative medicine
  • Pharma and biotech companies developing cell therapies
  • Cosmetics companies developing skin products
What

Formats

  • Aggregate reports by age group and concern
  • Research datasets of before and after records
  • Custom aggregates for study design
Why

Why it has value

  • Before and after recorded with the same questions
  • Photos and surveys linked to the same person
  • Usable because purpose specific consent is attached
Data provision principles

What we provide and what we never provide

What we provide

  • Aggregate data processed so individuals cannot be identified
  • Only records whose owners consented to that purpose
  • Public disclosure of recipients and purposes

What we never provide

  • Names, contact details or original face photos
  • Personal data for advertising or sales
  • Records of anyone who withdrew consent
Participants

Point benefits

Complete your profile and save your health survey to qualify for the optional one-time reward. Research participation is a separate choice.

Network Planned

Network revenue

Revenue from data provision is counted as network revenue.

Token Planned

Purchase and burn policy

A share of network revenue is used for purchase and burn under a published policy. It is a disclosed policy, not a promise.

Retention periods, cross border transfers and access rights will be published in the privacy policy before collection begins.